ViralStatDx in Action
ViralStatDx generates rapid results with 99% accuracy
How it Works
Recent metabolomics studies clearly show elevated levels of biological markers when an individual is infected with Covid-19, Influenza, Nipah, and Noroviruses. Therefore, a patient infected with any of these viruses will have a higher biological marker count specific to their ailment than a healthy individual.
This increase in biological markers is detectable by ViralStatDx through its innovative detection technology. With its high sensitivity, ViralStatDx differentiates between ailments rapidly with very high accuracy. Results are both qualitative and quantitative.
The software used to interpret the analyzed data is customizable to the users experience including pre-screening and post-screening patient profiling, language, and more.
Fast, Easy to Use, and Reliable
Testing methodology such as RT-PCR can only be done in reference lab settings and results usually take 1 to 2 days making Point of Care (POC) screening very difficult. Additionally, RT-PCR testing must be performed by someone properly credentialed. Finally, RT-PCR is less than 70% accurate and is not reliable for testing large groups of individuals at a time.
ViralStatDx is the size of a large desktop computer and provides a result in under 14 seconds. This setup is ideal for large group settings and Point of Care testing. Any layperson can learn how to operate ViralStatDx in less than a day.
In addition to speed and ease of use, ViralStatDx is more reliable than current industry screening standards. Recent studies for detecting COVID-19 and Influenza with ViralStatDx provided the following results: 100% sensitivity, 99% accuracy, and 98.85% specificity.